Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

May 24, 2015 4:47 PM ET


Company Overview of Hoffmann-La Roche Inc.

Company Overview

Hoffmann-La Roche Inc., also known as Roche, researches, develops, and manufactures medicines, diagnostics, and vitamins. It offers drugs and in-vitro diagnostics for cancer and transplantation; and therapeutic products for cancer, neuroscience, infectious diseases, immunology, cardiovascular, and metabolism diseases. Hoffmann-La Roche Inc. was formerly known as Roche Chemical Works Inc. and changed its name to Hoffmann-La Roche Inc. in 1929. The company was founded in 1905 and is headquartered in Nutley, New Jersey. Hoffmann-La Roche Inc. operates as a subsidiary of Roche Holding AG.

340 Kingsland Street

Nutley, NJ 07110

United States

Founded in 1905





Key Executives for Hoffmann-La Roche Inc.

Chief Executive Officer and President
Age: 59
Senior Principal Scientist of Respiratory Inflammation and Autoimmune Diseases
Global Head of Roche Pharma Partnering
Age: 55
Head of Roche Pharmaceuticals Western Europe Region
Age: 56
Managing Director
Compensation as of Fiscal Year 2014.

Hoffmann-La Roche Inc. Key Developments

Hoffmann-La Roche Inc. Presents at Boston Biotech Conferences LLC's The New York CEO Conference, Nov-13-2013 01:20 PM

Hoffmann-La Roche Inc. Presents at Boston Biotech Conferences LLC's The New York CEO Conference, Nov-13-2013 01:20 PM. Venue: Apella, 450 East 29th Street, New York, NY 10016, United States. Speakers: Bob Silverman.

Intas Pharma Signs Settlement and License Agreement with Roche for Xeloda

Intas Pharmaceuticals and its subsidiary Accord Healthcare Inc. announced that it has entered into a settlement and license agreement with Hoffmann-La Roche Inc. that will resolve pending patent litigation related to Xeloda Tablets, 150 mg and 500 mg, known generically as Capecitabine Tablets. This product is an orally administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Xeloda Tablets had U.S. sales of approximately $706.2 million for the 12 months ending Dec. 31, 2012, according to IMS Health. Intas reported that Hoffmann-La Roche Inc. had filed patent infringement suit against Accord Healthcare and Intas Pharmaceuticals following Accord's submission to the U.S. Food and Drug Administration of an Abbreviated New Drug Application (ANDA) for a generic version of Xeloda Tablets. As part of the agreement, the Company said that Hoffman La Roche Inc. has granted Accord a license to enter the U.S. market with a generic version of Xeloda Tablets ahead of its exclusivity period. Pursuant to the agreement, pending litigation would be dismissed. All other terms and conditions of the settlement are confidential, and the agreement itself is subject to review by the U.S. Department of Justice and the Federal Trade Commission.

Similar Private Companies By Industry

Company Name Region
Major Pharmaceuticals, Inc. United States
Locus Pharmaceuticals, Inc. United States
Exsulin Corporation United States
OrPro Therapeutics, Inc. United States
Colby Pharmaceutical Company United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Hoffmann-La Roche Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at